Published • loading... • Updated
ESMO 2026 Preview | Mabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Negative Breast Cancer
- Mabwell will present Phase II results for its Nectin-4-targeting ADC 9MW2821 at the 2026 European Society for Medical Oncology Congress.
- The study evaluates 9MW2821 alone or with a PD-1 antibody in patients with advanced TNBC previously treated with a Topo I ADC.
- Among 60 evaluable patients, the objective response rate was 30.0%, the disease control rate was 80.0%, and median progression-free survival was 3.7 months.
- Mabwell reported no new safety signals, and described 9MW2821’s safety profile as manageable.
Insights by Ground AI
17 Articles
17 Articles
keenesentinel.com+15 Reposted by 15 other sources
ESMO 2026 Preview | Mabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Negative Breast Cancer
SHANGHAI, Oct. 18, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present Phase II clinical data on its Nectin-4-targeting antibody-drug conjugate (ADC) 9MW2821 (Bulumtatug Fuvedotin, "BFv") in locally advanced or metastatic…
Coverage Details
Total News Sources17
Leaning Left2Leaning Right4Center8Last UpdatedBias Distribution57% Center
Bias Distribution
- 57% of the sources are Center
57% Center
14%
C 57%
R 29%
Factuality
To view factuality data please Upgrade to Premium
